These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12476958)

  • 1. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases.
    Girolomoni G; Pastore S; Albanesi C; Cavani A
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1590-5. PubMed ID: 12476958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis: targeting therapy towards the inflammatory cascade.
    Miteva M
    Am J Clin Dermatol; 2010; 11 Suppl 1():11-3. PubMed ID: 20586499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.
    Choi B; Hwang Y; Kwon HJ; Lee ES; Park KS; Bang D; Lee S; Sohn S
    J Dermatol Sci; 2008 Nov; 52(2):87-97. PubMed ID: 18585901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
    Surguladze D; Deevi D; Claros N; Corcoran E; Wang S; Plym MJ; Wu Y; Doody J; Mauro DJ; Witte L; Busam KJ; Pytowski B; Rodeck U; Tonra JR
    Cancer Res; 2009 Jul; 69(14):5643-7. PubMed ID: 19584274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor and anti-tumor necrosis factor therapies.
    Keystone EC; Ware CF
    J Rheumatol Suppl; 2010 May; 85():27-39. PubMed ID: 20436163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophilic dermatoses: a review of current treatment options.
    Cohen PR
    Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
    Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P
    Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of a local overproduction of tumor necrosis factor-α in complex regional pain syndrome.
    Walker S; Drummond PD
    Pain Med; 2011 Dec; 12(12):1784-807. PubMed ID: 22082181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor necrosis factor-alpha in the therapy of psoriasis.
    Gisondi P; Gubinelli E; Cocuroccia B; Girolomoni G
    Curr Drug Targets Inflamm Allergy; 2004 Jun; 3(2):175-83. PubMed ID: 15180471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
    Sweiss NJ; Curran J; Baughman RP
    Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha.
    MclInnes IB
    Ernst Schering Res Found Workshop; 2006; (56):29-44. PubMed ID: 16329645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms for modulating TNF alpha in immune and inflammatory disease.
    Baugh JA; Bucala R
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):635-50. PubMed ID: 12825458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Bedside to Bench: the Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory Diseases.
    Haraoui B; Russell AS; Keystone EC
    J Rheumatol Suppl; 2010 May; 85():1. PubMed ID: 20436160
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: an update.
    Giasuddin AS; Hoque ME; Ahmed ZU
    Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):88-94. PubMed ID: 17549869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of TNFalpha in ulcerative colitis.
    Sands BE; Kaplan GG
    J Clin Pharmacol; 2007 Aug; 47(8):930-41. PubMed ID: 17567930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases.
    Bressler B; Haraoui B; Keystone E; Sette A
    J Rheumatol Suppl; 2010 May; 85():40-52. PubMed ID: 20436164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.